SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-23-035291
Filing Date
2023-07-20
Accepted
2023-07-19 21:52:19
Documents
2
Group Members
DAVID C. OTTO. ANDREAS HALVORSENROSE S. SHABETVIKING GLOBAL EQUITIES MASTER LTD.VIKING GLOBAL OPPORTUNITIES GP LLCVIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTERVIKING GLOBAL OPPORTUNITIES PARENT GP LLCVIKING GLOBAL OPPORTUNITIES PORTFOLIO GP

Document Format Files

Seq Description Document Type Size
1 SC 13D/A brhc20056124_sc13da.htm SC 13D/A 353697
2 EXHIBIT 99.4 brhc20056124_ex99-4.htm EX-99.4 8893
  Complete submission text file 0001140361-23-035291.txt   364683
Mailing Address 55 RAILROAD AVENUE GREENWICH CT 06830
Business Address 55 RAILROAD AVENUE GREENWICH CT 06830 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

IRS No.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Subject) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91059 | Film No.: 231097967
SIC: 2834 Pharmaceutical Preparations